leadf
logo-loader
view4D pharma PLC
(
AIM:DDDDNASDAQ:LBPS
)

4D pharma inks clinical trial collaboration and supply agreement with Merck and Pfizer

As part of the tie-up, 4D pharma will start a clinical trial this year BAVENCIO, a drug for advanced or metastatic urothelial carcinoma

4D pharma PLC -

4D pharma PLC (LON:DDDD) has signed a clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc.

As part of the tie-up, 4D pharma will start a clinical trial this year with BAVENCIO, a drug for advanced or metastatic urothelial carcinoma developed by Merck and Pfizer, in combination with UK group’s MRx0518.

"With this second clinical trial collaboration for MRx0518 with a leading immune checkpoint inhibitor, 4D is able to evaluate MRx0518 in a new combination and earlier treatment setting,” said 4D chief executive Duncan Peyton.

MRx0518 has already generated “promising” early clinical data in harness with blockbuster cancer drug Keytruda, while its potential is also being assessed as a single therapy.

CEO Peyton said the latest collaboration would allow its scientists “to continue to build a broad understanding of the safety and efficacy of MRx0518 across a range of solid tumours and stages of the disease”.

He added: "The combination of MRx0518 with BAVENCIO has the potential to further enhance the positive clinical outcomes achieved by BAVENCIO for the significant number of patients in this treatment setting."

Working in the emerging area of the human microbiome (the bacteria that reside mainly in the gut), 4D has developed Live Biotherapeutics — products that contain live organisms such as human commensal bacteria.

The approach focuses on single strains to assess specific mechanisms of action targeting a defined disease pathway.

Even variations between different strains of bacteria of the same species are assessed and exploited.

Peyton says superficially identical bacteria can sometimes differ up to 20% in their gene content, and therefore may have highly different functional profiles.

Toxicity has always been a major impediment to the success of new drugs.

In developing its Live Biotherapeutics, 4D has isolated bacteria from healthy human donors which are expected to have “highly attractive safety profiles”.

Quick facts: 4D pharma PLC

Follow
AIM:DDDD

Price: 64 GBX

Market Cap: £115.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE rides on wave of results and reopening optimism boosts the market mood

FTSE 100 rose as a wave of results and reopening optimism boosted the mood on investors. Anglo American and Shell were good, BT not so much and the blue-chip index was up 45 at points at 7,061. Lloyds Banking Group (LSE:LLOY) PLC declared its first interim dividend after the recent removal of...

on 29/7/21

2 min read